Form 4: Rhythm Pharmaceuticals Director Reports Net Share Disposition Following RSU Vesting

Lynn A. Tetrault, a Director at Rhythm Pharmaceuticals, Inc. (RYTM), reported the vesting and acquisition of 4,000 common shares from Restricted Stock Units, alongside a disposition of 7,000 common shares, resulting in a net reduction of 3,000 shares on June 18, 2025.

Summary

• Lynn A. Tetrault, a Director of Rhythm Pharmaceuticals, Inc. (RYTM), filed a Form 4 reporting transactions on June 18, 2025.
• The filing indicates the exercise/vesting of 4,000 Restricted Stock Units (RSUs), which converted into 4,000 shares of common stock.
• Concurrently, 7,000 shares of common stock were disposed of on the same date.
• This results in a net disposition of 3,000 common shares (7,000 disposed 4,000 acquired) from these reported transactions.
• The Restricted Stock Units fully vested on June 18, 2025, and had no expiration date.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the net disposition of shares by a director, even though it's related to RSU vesting. While such sales often cover tax obligations, a net reduction in insider holdings can sometimes be viewed with caution by the market.

Positives

• The vesting of 4,000 Restricted Stock Units indicates a planned compensation event for a director, aligning their interests with shareholder value through equity awards.

Negatives

• The net disposition of 3,000 common shares by a director could be perceived negatively by investors, as it represents a reduction in their direct equity holdings in the company.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends, but rather reflects a director's personal stock activity related to their compensation.

Stakeholder Impact

• Shareholders may observe the director's net reduction in common stock holdings, which could influence their perception of insider confidence, although such transactions are often for tax or personal liquidity reasons.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, Lynn A. Tetrault, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Common Stock, Director Stock Sale, Equity Compensation